Your browser is no longer supported. Please, upgrade your browser.
Settings
JAZZ Jazz Pharmaceuticals Public Limited Company daily Stock Chart
JAZZ [NASD]
Jazz Pharmaceuticals Public Limited Company
Index- P/E29.17 EPS (ttm)5.23 Insider Own2.70% Shs Outstand60.97M Perf Week-1.42%
Market Cap9.30B Forward P/E11.73 EPS next Y12.99 Insider Trans-6.09% Shs Float58.05M Perf Month12.48%
Income329.50M PEG1.50 EPS next Q2.35 Inst Own96.40% Short Float2.63% Perf Quarter24.98%
Sales1.32B P/S7.02 EPS this Y460.60% Inst Trans-0.33% Short Ratio2.24 Perf Half Y11.06%
Book/sh26.00 P/B5.86 EPS next Y16.81% ROA9.80% Target Price176.07 Perf Year-16.79%
Cash/sh- P/C- EPS next 5Y19.42% ROE22.30% 52W Range108.50 - 194.73 Perf YTD8.47%
Dividend- P/FCF18.75 EPS past 5Y44.40% ROI13.70% 52W High-24.30% Beta0.72
Dividend %- Quick Ratio5.50 Sales past 5Y50.10% Gross Margin92.30% 52W Low35.87% ATR5.04
Employees910 Current Ratio5.50 Sales Q/Q3.90% Oper. Margin37.10% RSI (14)53.37 Volatility2.70% 3.19%
OptionableYes Debt/Eq0.75 EPS Q/Q16.20% Profit Margin24.90% Rel Volume0.74 Prev Close152.47
ShortableYes LT Debt/Eq0.73 EarningsMay 10 AMC Payout0.00% Avg Volume681.08K Price147.42
Recom1.80 SMA20-0.69% SMA509.85% SMA2002.71% Volume288,372 Change-3.31%
Apr-25-16Upgrade Sun Trust Rbsn Humphrey Neutral → Buy
Feb-24-16Reiterated Mizuho Neutral $140 → $124
Feb-19-16Initiated Wells Fargo Outperform
Nov-25-15Initiated Bernstein Mkt Perform
Nov-10-15Downgrade Mizuho Buy → Neutral $164 → $140
Oct-14-15Initiated Northland Capital Outperform $200
Oct-09-15Initiated Mizuho Buy
Jun-29-15Reiterated UBS Buy $190 → $210
May-26-15Reiterated Guggenheim Buy $210 → $220
Feb-25-15Reiterated Deutsche Bank Buy $176 → $185
Feb-20-15Initiated BMO Capital Markets Outperform $200
Nov-05-14Upgrade R. F. Lafferty Neutral → Buy $200
May-09-14Reiterated R. F. Lafferty Neutral $140 → $130
Apr-17-14Initiated Canaccord Genuity Buy $163
Mar-07-14Resumed Barclays Overweight $200
Feb-26-14Reiterated Stifel Buy $145 → $195
Jan-14-14Reiterated UBS Buy $130 → $164
Jan-14-14Downgrade R. F. Lafferty Buy → Neutral $140
Dec-06-13Reiterated UBS Buy $110 → $130
Nov-25-13Reiterated FBR Capital Outperform $105 → $198
May-04-16 08:07AM  Arena (ARNA) Q1 Earnings: What's in Store for the Stock? Zacks
May-03-16 06:57PM  Conatus (CNAT): Can the Stock Surprise in Q1 Earnings? Zacks
06:45PM  What's Up at GW Pharmaceuticals (GWPH) in Q2 Earnings? Zacks
06:38PM  What's in Store for Agios (AGIO) This Earnings Season? Zacks
04:39PM  Here's Why Jazz Pharmaceuticals PLC Was on the Receiving End of a 15% Boost in April at Motley Fool
12:05PM  What Can We Expect from Jazz Pharmaceuticals in 2016? Market Realist
10:43AM  Intercept (ICPT): Stock Likely to Disappoint in Q1 Earnings Zacks
Apr-26-16 08:05PM  How Did Jazz Pharmaceuticals Products Perform in 2015? Market Realist
07:08PM  What Do Analysts Recommend for Jazz Pharmaceuticals? Market Realist
04:05PM  Jazz Pharmaceuticals to Report 2016 First Quarter Financial Results on May 10, 2016 PR Newswire
09:07AM  Can Xyrem Maintain Leadership in the Narcolepsy Space? Market Realist
Apr-25-16 06:56AM  Jazz Pharma upgraded by Sun Trust Rbsn Humphrey Briefing.com
Apr-21-16 03:18PM  Why Does Jazz Pharmaceuticals Have a Lower Valuation Than Peers? Market Realist
03:18PM  Jazz Pharmaceuticals: How Does Its Earnings Multiple Compare? Market Realist
Apr-15-16 10:19PM  Fund Managers Injecting Money Into This Top Medical Research Stock
Apr-13-16 04:17PM  Valeant CEO Is Brave; Clovis PT Slashed; Buy Jazz Aggressively? +5.49%
10:28AM  Stocks Rumble Higher In Fat Trade: Early Risers: Tenet Health, Jazz
Apr-08-16 02:46PM  [$$] Four Buys After the Specialty-Pharma Selloff at Barrons.com
Apr-07-16 05:58PM  Final Trade: KB Homes, Jazz Pharmaceuticals, & more
Apr-06-16 05:40PM  The Allergan 'Dating Game' +5.42%
Apr-01-16 10:15AM  Jazz Pharmaceuticals Plc Value Analysis (NASDAQ:JAZZ) : April 1, 2016
07:59AM  Jazz Securities Limited -- Moody's: Approval of Jazz's Defitelio by the FDA is credit positive; ratings unaffected at Moody's
Mar-31-16 04:40PM  Jazz's Hepatic VOD Drug Defitelio Gains FDA Nod, Shares Up +5.26%
08:04AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : March 31, 2016
Mar-30-16 05:27PM  Citigroup, Amgen Are Trading With Wide Margin of Safety
02:41PM  Jazz Pharmaceuticals Announces Webcast for Defitelio® (defibrotide sodium) Investor Update PR Newswire
02:32PM  Jazz Pharmaceuticals Announces FDA Approval of Defitelio® (defibrotide sodium) for the Treatment of Hepatic Veno-Occlusive Disease (VOD) with Renal or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation (HSCT) PR Newswire
12:58PM  Rare liver disorder drug from Jazz wins U.S. approval Reuters
12:25PM  Jazz Pharmaceuticals' rare liver disorder drug wins U.S. approval Reuters
Mar-23-16 02:23PM  What's Going On With Kyle Bass And Biogen?
Mar-17-16 06:00AM  [video]'Mad Money' Lightning Round: Step Into Skechers Long Term at TheStreet
Mar-09-16 08:07AM  How Are IBBs Mid-Caps Faring as of March 7?
Mar-08-16 01:20PM  3 Reasons Jazz Pharmaceuticals Stock Could Rise in 2016 at Motley Fool
Mar-07-16 09:38AM  The Most Important FDA Decision We're Watching This Quarter at Motley Fool
Mar-02-16 04:05PM  Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March PR Newswire
Mar-01-16 10:16AM  Jazz Pharmaceuticals Plc Earnings Analysis: 2015 By the Numbers
Feb-27-16 01:04PM  JAZZ PHARMACEUTICALS PLC Financials
Feb-24-16 03:39PM  Jazz Pharma Falls After Q4 Sales Miss Street View
11:50AM  Jazz Tops Q4 Earnings, Revenues Up Y/Y, Gives 2016 View
12:15AM  Edited Transcript of JAZZ earnings conference call or presentation 23-Feb-16 9:30pm GMT
Feb-23-16 05:47PM  Jazz beats 4Q profit forecasts
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today
04:27PM  Earnings Recap For February 23
04:14PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2015 Financial Results PR Newswire
07:07AM  Q4 2015 Jazz Pharmaceuticals PLC Earnings Release - After Market Close
Feb-18-16 09:05AM  Jazz Pharmaceuticals To Present Data From Ongoing Evaluations Of Defibrotide At The 2016 BMT Tandem Meeting PR Newswire
Feb-09-16 04:05PM  Jazz Pharmaceuticals to Report 2015 Fourth Quarter and Full Year Financial Results on February 23, 2016 PR Newswire
Feb-08-16 06:37PM  Former Leaders Show Up On New Low List; D.R. Horton Sinks Again -6.25%
Feb-05-16 01:06PM  How to Play the Biotech Selloff at Barrons.com
Feb-02-16 04:40PM  Jazz's Phase III Data on Defibrotide Published in ASH Journal
09:04AM  Ignore Regeneron Pharmaceuticals, Inc: Here Are 3 Better Buys Right Now at Motley Fool
Feb-01-16 09:05AM  Results from Phase 3 Trial of Defibrotide for the Treatment of Severe Veno-Occlusive Disease and Multi-Organ Failure Published Online in BLOOD PR Newswire
Jan-27-16 01:30PM  One Stock You Need To Buy Now
Jan-21-16 04:33PM  Use Composite Rating To Help Narrow Stock Field at Investor's Business Daily
Jan-20-16 01:53PM  Over 1,000 Stocks On The NYSE Just Hit 52-Week Lows +6.57%
Jan-15-16 06:00PM  Walgreens, CVS, Illumina, Jazz Top New Insider Trades at Investor's Business Daily
Jan-14-16 04:53PM  3 Stocks To Watch In Thursday's After-Hours Session
Jan-12-16 04:20PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and +5.16%
Jan-08-16 07:20AM  4 Pharmaceutical Stocks With Big Catalysts Pending in 2016 at 24/7 Wall St.
Jan-04-16 04:05PM  Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 11 PR Newswire
Jan-01-16 08:08AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : January 1, 2016
Dec-31-15 01:59PM  Drug Makers: Valeant's M&A Prospects in 2016 at Barrons.com
Dec-14-15 08:45AM  Jazz Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : December 14, 2015
Dec-04-15 01:43PM  Hedge Funds Like These Five Declining Stocks in Q4 at Insider Monkey
Dec-03-15 06:11PM  U.S.-Traded Eurozone Stocks React Mildly To ECB Vote at Investor's Business Daily
Dec-02-15 10:56AM  Here is What Hedge Funds Think About Michael Kors Holdings Ltd (KORS) at Insider Monkey
Nov-30-15 08:03PM  Smart Money is Flowing Into Jazz Pharmaceuticals plc (JAZZ) at Insider Monkey
07:03AM  3 Companies That Could Become Tax Inversion Targets at Motley Fool
Nov-29-15 03:08AM  Should You Avoid InterContinental Hotels Group PLC (ADR) (IHG)? at Insider Monkey
Nov-26-15 04:35AM  F5 Networks, Inc. (FFIV): Are Hedge Funds Right About This Stock? at Insider Monkey
Nov-25-15 05:33PM  Don't Forget Hot Sectors When Looking For New Stocks at Investor's Business Daily
Nov-16-15 01:43PM  These Biotech Stocks May Start Paying Dividends in 2016 at Motley Fool
Nov-15-15 08:11AM  3 Great Stocks on Sale at Motley Fool
Nov-11-15 09:30AM  Jazz's Q3 Earnings & Revenues Grow Y/Y; Trims 2015 Outlook
Nov-10-15 01:34PM  3 Midsize Drug Stocks Moving On Q3 Reports at Investor's Business Daily
Nov-09-15 07:09PM  Jazz misses Street 3Q forecasts
05:43PM  After-hours buzz: Gap, Rackspace, Caesars & more at CNBC
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today
04:21PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:18PM  Jazz Pharmaceuticals (JAZZ) Stock Falls in After-Hours Trading on Earnings Miss at TheStreet
04:05PM  Jazz Pharmaceuticals Announces Third Quarter 2015 Financial Results PR Newswire
07:07AM  Q3 2015 Jazz Pharmaceuticals PLC Earnings Release - After Market Close
Nov-05-15 03:00PM  2 Hot Upcoming Healthcare Earnings Calls
Nov-04-15 04:05PM  Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences PR Newswire
Nov-02-15 07:34AM  3 Stocks to Buy Now in Biotech at Motley Fool
Oct-30-15 03:07PM  Shire Helped IBBs Top 10 Large-Cap Pharma Stocks Outperform XLV
Oct-28-15 01:53PM  Jazz Pharmaceuticals Plc Value Analysis (NASDAQ:JAZZ) : October 28, 2015
Oct-26-15 04:05PM  Jazz Pharmaceuticals to Report 2015 Third Quarter Financial Results on November 9, 2015 PR Newswire
09:02AM  Super Stock Case Study - IBD Investing Show Excerpt
Oct-24-15 01:02PM  Better Buy Now: Medivation Inc vs Jazz Pharmaceuticals at Motley Fool
12:44PM  Amazon, Alphabet/Google, Microsoft Earnings Beats - IBD Investing Show
Oct-23-15 09:08AM  ALNY and JAZZ Hindered the Top 10 Mid-Cap Stocks on October 21 +5.11%
Oct-18-15 08:51AM  5 Trade Ideas for Monday: CononcoPhillips, Discover, Electronic Arts, Jazz and Packaging Corp.
Oct-14-15 07:08PM  3 Value Stocks Near 52-Week Lows Worth Buying at Motley Fool
09:36AM  Northland Starts Jazz Pharma, Mallinckrodt, Shire With Outperform Ratings
Oct-10-15 03:26AM  Jazz Pharmaceuticals Is Cheap at Barrons.com
Oct-09-15 04:23PM  Tesla Downgraded On Model X; Jazz, Allergan Get Buys at Investor's Business Daily
11:25AM  How To Invest During Biotech's Latest Crisis
Oct-07-15 04:09PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, a late-stage investigational compound, which is in phase III clinical trail for the treatment of EDS in narcolepsy and obstructive sleep apnea; and JZP-386, a deuterium-modified analog of sodium oxybate that is completed phase I clinical trail for use in patients with narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WILSON KAREN JSVP, Finance & PAOApr 25Sale160.0060496,64018,059Apr 27 06:15 PM
MILLER MICHAEL PATRICKSVP, US CommercialApr 15Sale145.7910014,57918,792Apr 18 05:04 PM
Cox Russell J.EVP & COOApr 12Sale136.984,000547,92060,470Apr 13 04:29 PM
WILSON KAREN JSVP, Finance & PAOApr 07Sale140.902,161304,48523,670Apr 08 04:43 PM
MILLER MICHAEL PATRICKSVP, US CommercialMar 15Sale129.1710012,91718,892Mar 16 05:48 PM
COZADD BRUCE CChairman & CEOMar 08Sale126.042,500315,100300,066Mar 09 07:26 PM
Treacy PaulSVP, Technical OperationsFeb 29Sale123.4835443,71215,100Mar 02 05:59 PM
Mulligan SeamusDirectorFeb 23Sale122.7127,9683,431,9041,102,579Feb 24 07:56 PM
COZADD BRUCE CChairman & CEOFeb 09Sale111.372,500278,425281,896Feb 11 05:01 PM
MILLER MICHAEL PATRICKSVP, US CommercialJan 15Sale122.6610012,26613,561Jan 21 11:43 AM
COZADD BRUCE CChairman & CEOJan 12Sale123.812,500309,525284,396Jan 14 06:52 PM
ENRIGHT PATRICK GDirectorJan 05Sale138.0910,0001,380,8904,519Jan 07 04:46 PM
MILLER MICHAEL PATRICKSVP, US CommercialDec 15Sale136.9910013,69913,661Dec 17 04:11 PM
ENRIGHT PATRICK GDirectorDec 02Sale148.4942462,9601,310Dec 03 04:29 PM
ENRIGHT PATRICK GDirectorDec 01Sale146.5910,0001,465,9104,716Dec 03 04:29 PM
Mulligan SeamusDirectorNov 23Sale147.9010,2431,514,9281,130,547Nov 24 06:50 PM
Mulligan SeamusDirectorNov 20Sale144.6817,7252,564,3681,140,790Nov 24 06:50 PM
MILLER MICHAEL PATRICKSVP, US CommercialNov 16Sale134.0310013,40313,690Nov 17 08:47 PM
McGill IainSVP, Europe & Rest of WorldNov 13Sale135.672,821382,73719,146Nov 17 05:24 PM
ENRIGHT PATRICK GDirectorNov 10Sale135.2910,0001,352,8624,912Nov 12 04:25 PM
COZADD BRUCE CChairman & CEONov 10Sale128.532,500321,325289,355Nov 12 07:19 PM
COZADD BRUCE CChairman and CEOOct 13Sale131.502,500328,750291,855Oct 15 04:04 PM
ENRIGHT PATRICK GDirectorOct 05Sale133.7910,0001,337,8605,108Oct 07 04:13 PM
MILLER MICHAEL PATRICKSVP, US CommercialSep 25Sale145.2310014,52313,890Sep 29 06:56 PM
COZADD BRUCE CChairman and CEOSep 08Sale163.072,500407,679294,355Sep 09 07:14 PM
ENRIGHT PATRICK GDirectorSep 01Sale165.9910,0001,659,8525,304Sep 03 04:03 PM
ENRIGHT PATRICK GDirectorAug 27Sale167.8742571,3451,734Aug 31 04:06 PM
Sohn Catherine A.DirectorAug 11Sale177.82654116,2935,384Aug 11 05:44 PM
COZADD BRUCE CChairman and CEOAug 11Sale177.822,500444,550296,855Aug 12 05:35 PM
Hooper Suzanne SawochkaEVP and General CounselAug 11Sale177.824,000711,28037,855Aug 12 05:33 PM
Cox Russell J.EVP & Chief Commercial OfficerAug 11Sale177.8250088,91058,602Aug 12 05:31 PM
Treacy PaulSVP, Technical OperationsAug 11Sale177.821,330236,49411,401Aug 11 05:54 PM
Winningham Rick EDirectorAug 10Sale180.00801144,17814,659Aug 11 05:46 PM
Sohn Catherine A.DirectorAug 10Sale180.00801144,1806,038Aug 11 05:44 PM
RIEDEL NORBERT GDirectorAug 10Sale180.00801144,1784,865Aug 11 05:41 PM
McSharry Heather AnnDirectorAug 10Sale179.99867156,0526,093Aug 11 05:37 PM
Gray PeterDirectorAug 10Sale180.00867156,0595,389Aug 11 05:35 PM
ENRIGHT PATRICK GDirectorAug 10Sale182.0210,0001,820,1775,500Aug 11 05:34 PM
ENRIGHT PATRICK GDirectorAug 10Sale180.00801144,1782,159Aug 11 05:34 PM
BERNS PAUL LDirectorAug 10Sale180.00801144,1785,589Aug 11 05:32 PM
Hooper Suzanne SawochkaEVP & General CounselJul 14Option Exercise46.834,000187,32050,420Jul 16 05:47 PM
Hooper Suzanne SawochkaEVP & General CounselJul 14Sale177.794,000711,16046,420Jul 16 05:47 PM
COZADD BRUCE CChairman & CEOJul 14Sale177.795,000888,950542,224Jul 16 05:47 PM
ENRIGHT PATRICK GDirectorJul 06Sale177.1110,0001,771,0555,696Jul 08 04:03 PM
Hooper Suzanne SawochkaEVP & General CounselJun 09Option Exercise46.834,000187,32050,420Jun 11 05:37 PM
Hooper Suzanne SawochkaEVP & General CounselJun 09Sale173.164,000692,64046,420Jun 11 05:37 PM
WILSON KAREN JSVP, Finance & PAOJun 02Sale180.0025746,26025,642Jun 03 06:34 PM
WILSON KAREN JSVP, Finance & PAOJun 01Option Exercise50.195,494275,73429,893Jun 03 06:34 PM
ENRIGHT PATRICK GDirectorJun 01Sale178.7310,0001,787,3365,893Jun 03 04:04 PM
WILSON KAREN JSVP, Finance & PAOJun 01Sale179.575,494986,54825,899Jun 03 06:34 PM
McGill IainSVP, Europe and Rest of WorldMay 26Option Exercise49.357,334361,90132,030May 28 07:11 PM
McGill IainSVP, Europe and Rest of WorldMay 26Sale179.487,3341,316,32624,696May 28 07:11 PM
O'Keefe Kenneth WDirectorMay 12Option Exercise46.834,500210,73510,650May 14 08:19 PM
Hooper Suzanne SawochkaEVP & General CounselMay 12Option Exercise46.832,07397,07950,297May 14 08:30 PM
RIEDEL NORBERT GDirectorMay 12Sale173.86650113,0104,356May 14 08:12 PM
Gray PeterDirectorMay 12Sale173.86704122,4004,946May 14 07:58 PM
Hooper Suzanne SawochkaEVP & General CounselMay 12Sale173.854,000695,40046,297May 14 08:30 PM
COZADD BRUCE CChairman & CEOMay 12Sale173.855,000869,250551,967May 14 08:25 PM
O'Keefe Kenneth WDirectorMay 12Sale174.901,218213,0269,432May 14 08:19 PM
ENRIGHT PATRICK GDirectorMay 11Sale176.1810,0001,761,7966,089May 13 04:01 PM